Gazyva (obinutuzumab) is a lab-made antibody medication used for treating certain blood cancers. The FDA recently approved the combined use of Gazyva and standard therapy in adults having an active ...
The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...
In an exploratory analysis, obinutuzumab treatment significantly reduced the risk for lupus nephritis flare and unfavorable kidney outcomes compared with placebo. Obinutuzumab significantly reduces ...
Gazyva dosage Gazyva dosage depends on many factors, including what condition you have, what cycle of chemotherapy you are in, and other medical conditions that you may have. Your doctor will be able ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results